Performance Shares, page-2

DB: There were 628 samples in the LC-POC and LC-600 studies. I copied some relevant info. below:

Annual Report 2018

BARD1 plans to develop BARD1-Lung as anaccurate and reliable screening test for early detection of lung cancer, theleading cause of cancer death in men and women.

Previous research including the LC-POCStudy and the LC-600 Study demonstrated the potential of further developingBARD1-Lung as a highly sensitive and specific blood test for early detection oflung cancer using additional biomarkers and gender-specific algorithms.

On 7 August 2017, a key paper on theoriginal lung cancer POC Study results and underlying scientific methodologyfor the BARD1-Lung test was published in international peer-reviewed journalPLoS ONE. The paper titled ‘BARD1 serum autoantibodies for early detection oflung cancer’ describes a simple and reliable blood test for early detection ofall types of lung cancer based on the immunogenicity of aberrant forms of BARD1protein that are upregulated in lung cancer. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0182356

Continuation of the lung cancer program iscurrently planned upon successful transfer of the BARD1-Ovarian test to theLuminex® platform.

Further case-control studies are plannedfor 2019 to optimise the BARD1-Lung test using the new multiplex BARD1 assay,additional biomarkers and gender-specific algorithms, followed by developmentand analytical validation of the refined BARD1-Lung on Luminex®instrumentation, before advancing towards clinical studies.

Quarterly Business Update 31 Oct 2018

No new studies were conducted forBARD1-Lung during the quarter. The global lung cancer diagnostics market wasvalued at US$26.0b in 2013.

Quarterly Business Update 25 Jan 2019

No new studies were conducted forBARD1-Lung during the quarter.

Intellectual Property (IP) Portfolio update: Chinese Divisional Patent No 201610347489.9 titled “BARD1 isoforms in lung and colorectal cancer and use thereof” was granted by the China National Intellectual Property Administration (CNIPA). This patent provides additional coverage over the parent case for specific BARD1 isoforms, various methods and kits for use in the detection of the specific BARD1 isoforms, and methods for treatment or prevention of lung and colorectal cancer. Importantly, this patent provides additional IP protection for the BARD1-Lung cancer test (see ASX announcement 24/10/18).